pharma · Hypertension · Breast Neoplasms
Pfizer
NovaPharmaNews editorial coverage mentioning Pfizer — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- New York 10017, US
- Employees
- 103,316
- Programs
- 98
- Drugs
- 80
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Pfizer — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Pfizer — regulatory, clinical, and market analysis.
Eye drugs list: Sodium hyaluronate, tafluprost, tobramycin uses
This plan organizes a tightly sourced Eye drugs list around dry eyes, glaucoma, and eye infections. It keeps the focus on what the evidence confirms and avoids unsupported market or investment claims.
Danuglipron Phase 3 Watch After Pfizer’s Phase 2b Obesity Win
Pfizer said its oral GLP-1 danuglipron met the primary endpoint in a Phase 2b obesity trial, showing a statistically significant change in body weight from baseline. The result strengthens the case for Pfizer's oral GLP-1 strategy and sets up investor and BD scrutiny around Phase 3 design, safety, and differentiation.
Pfizer's Danuglipron Hits Phase 2b Obesity Endpoint
Pfizer said danuglipron, its oral GLP-1 receptor agonist, met the primary endpoint in a Phase 2b obesity trial with statistically significant weight loss versus baseline. The result strengthens the case for Danuglipron Phase 3 planning and gives BD and investor teams a fresh benchmark against other oral GLP-1 programs.
Pfizer's Berobenatide Obesity Drug: VESPER-3 Data and Competitive Outlook
Pfizer's monthly GLP-1 RA berobenatide (acquired from Metsera) shows continued weight loss in VESPER-3 Phase 2b data. This analysis covers efficacy, safety, and strategic implications for pharma teams.
Pfizer's Berobenatide: Monthly Obesity Drug Shows Promise in Phase 2b
New Phase 2b data for Pfizer's berobenatide (formerly MET097) show robust and continuous weight loss with monthly dosing, reinforcing its potential as a differentiated obesity therapy. The results offer key insights for analysts and BD teams tracking the Pfizer weight loss drug name and the broader obesity pipeline.
Rx Rundown: Pfizer, Hikma Pharmaceuticals, NewLimit — Drug Approvals & Catalyst Tracker
Pfizer, Hikma Pharmaceuticals, and NewLimit are at the center of recent FDA actions. This rundown covers approvals, withdrawals, and upcoming catalysts for pharma BD and investors.